tiprankstipranks
Trending News
More News >
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
US Market

TransCode Therapeutics (RNAZ) Income Statement

Compare
418 Followers

TransCode Therapeutics Income Statement

Last quarter (Q1 2025), TransCode Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q1, TransCode Therapeutics's net income was $-12.09M. See TransCode Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ -98.61K$ -42.47K$ 0.00
Operating Expenses
$ 15.66M$ 19.42M$ 17.59M$ 5.87M$ 726.60K
Depreciation and Amortization
$ 534.86K$ 516.75K$ 98.61K$ 42.47K$ 726.60K
EBITDA
$ -16.19M$ -17.97M$ -17.47M$ -6.11M$ 0.00
Operating Income
$ -15.66M$ -19.42M$ -18.67M$ -6.15M$ -726.60K
Other Income/Expenses
$ -1.12M$ 872.42K$ 1.10M$ -692.26K$ -1.62M
Pretax Income
$ -16.79M$ -18.55M$ -17.56M$ -6.84M$ -2.34M
Net Income
$ -16.75M$ -18.55M$ -35.13M$ -6.94M$ -2.74M
Per Share Metrics
Basic EPS
$ -47.14$ -3.45K$ -73.19K$ -648.00$ -293.76
Diluted EPS
$ -47.14$ -3.45K$ -1.08K$ -648.00$ -293.76
Weighted Average Shares Outstanding
356.12K- 16.22K 10.53K 7.98K
Weighted Average Shares Outstanding (Diluted)
356.12K- 16.22K 10.53K 7.98K
Currency in USD

TransCode Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis